Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis | Synapse
April 19, 2026Open Access
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Puntos clave
This research aims to characterize and manage adverse events following treatment with repotrectinib.
Analyzed adverse events associated with repotrectinib treatment.
Evaluated the effectiveness of dose modifications.
Assessed pharmacologic interventions for managing neurological adverse events.
Many adverse events were identified following repotrectinib treatment.
Neurological adverse events were mitigated with appropriate management strategies.
Dose modifications and pharmacologic interventions proved effective in managing adverse events.
Resumen
Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.